Vanitha Ramakrishnan

Vanitha Ramakrishnan

UNVERIFIED PROFILE

Are you Vanitha Ramakrishnan?   Register this Author

Register author
Vanitha Ramakrishnan

Vanitha Ramakrishnan

Publications by authors named "Vanitha Ramakrishnan"

Are you Vanitha Ramakrishnan?   Register this Author

15Publications

445Reads

19Profile Views

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

Clin Cancer Res 2013 Dec 18;19(24):6976-86. Epub 2013 Oct 18.

Authors' Affiliations: Oncology Biomarker Development, Portfolio Management and Operations, Translational Oncology, Biostatistics, and Exploratory Clinical Development, Genentech Inc., DNA Way, South San Francisco, California; Experimental Therapeutics, Molecular Pathology, Breast Cancer and Melanoma, Gastrointestinal and Endocrine Tumors Groups, and Medical Oncology Service, Vall d'Hebron Institute of Oncology, Barcelona; Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; and Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0978DOI Listing
December 2013

Investigational antibody-drug conjugates for hematological malignancies.

Expert Opin Investig Drugs 2011 Jan 11;20(1):75-85. Epub 2010 Dec 11.

Genentech, Inc., Department of Translational Oncology, 1 DNA way, Mail Stop 72A, South San Francisco 94080, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2011.539557DOI Listing
January 2011

Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.

Invest New Drugs 2008 Feb 1;26(1):7-12. Epub 2007 Sep 1.

PDL Biopharma, Inc., 34801 Campus Drive, Fremont, CA 94555, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-007-9078-zDOI Listing
February 2008